Company intelligence / Profile preview

Intersect ENT

Menlo Park, California, United States

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

Intersect ENT developed and commercialized the first FDA-approved bioabsorbable steroid-eluting sinus stents for chronic rhinosinusitis. Its lead products—PROPEL family and SINUVA—demonstrated efficacy in reducing post-surgical inflammation and recurrent nasal polyps. The company’s devices deliver targeted anti-inflammatory therapy directly to the sinuses with established safety and effectiveness in multiple clinical trials.

Therapeutic areas: ImmunologyPulmonology
Modalities: DeviceDrug-device combinationSmall molecule
Industry: Implantable Medical Devices

Drug pipeline

2 assets

PROPEL

Commercial

Indications: Chronic rhinosinusitis

1 more asset in the full pipeline.

Request access →

Partnerships

No major external pharma/biotech partnerships disclosed; previously VC-backed

Beyond the preview

Go deeper on Intersect ENT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intersect ENT.

Explore the full profile